Seeking Alpha

OncoSec Medical immunotherapy helps reduce tumors in mice

  • OncoSec Medical (ONCS.OB) says that combining ImmunoPulse DNA-based immunotherapy with anti-CTLA4 and anti-PD1 antibodies was effective in reducing tumors in a trial of 40 mice.
  • While the mice were treated with ImmunoPulse alone, or in combination with anti-CTLA4, anti-PD1 or both, there was 100% regression of treated lesions in all of the animals, with none dying due to toxicity.
  • OncoSec now intends to test various approaches in more aggressive melanoma models with a view to eventually carrying out human trials. (PR)
Comments (4)
  • TruffelPig
    , contributor
    Comments (4050) | Send Message
    It is obvious important to mention that clinical trials are ongoing in $ONCS. There are currently 3 phase II clinical trials and they got good data recently in humans:
    8 Oct 2013, 07:59 AM Reply Like
  • rhancock
    , contributor
    Comments (5) | Send Message
    $ONCS.OB....good science and has shown great results already. Great time to get in this stock
    8 Oct 2013, 10:22 AM Reply Like
  • Robbster
    , contributor
    Comments (46) | Send Message
    Yep, I'm with you on $ONCS.OB.
    8 Oct 2013, 11:15 PM Reply Like
  • Tile
    , contributor
    Comments (69) | Send Message
    8 Dec 2013, 10:27 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: